Guardant Health Q4 revenue $281.3M (+39% YoY); 2026 revenue guided $1.25-1.28B

Guardant Health, Inc.

2025-FY EPS reported -$3.32 revenue$982,021,000

Q4 total revenue $281.3M (+39% YoY); Oncology tests 79k (+38%), Screening tests 38k.
Full year 2025 revenue $982.0M (+33%); net loss $416.3M ($3.32 EPS) vs $436.4M prior year.
Adj. EBITDA loss improved to $220.9M (FY) from $257.5M; free cash flow burn $233M vs $275M.
2026 guidance: revenue $1.25-1.28B (27-30% growth); Screening revenue $162-174M; volume 210k-225k tests.
Acquired MetaSight Diagnostics for $59M upfront plus up to $90M contingent consideration.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.